Clinical breast cancer最新文献

{"title":"LINC00511 Promotes Breast Cancer Cell Proliferation and Invasion by Mediating MYC-Mediated Regulation of VASP","authors":"Sirui Huang ,&nbsp;Yiqing Xi ,&nbsp;Jingbo Gao ,&nbsp;Shilong Yu ,&nbsp;Le Chen ,&nbsp;Yuxia Duan ,&nbsp;Zelin Yang ,&nbsp;Yu Peng ,&nbsp;Lei Wei ,&nbsp;Jingwei Zhang","doi":"10.1016/j.clbc.2025.12.010","DOIUrl":"10.1016/j.clbc.2025.12.010","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer remains a significant health issue, with a persistent annual increase in incidence rates and high mortality. MYC, a critical transcription factor, is often dysregulated in breast cancer, driving tumor progression. Long noncoding RNAs (lncRNAs) have emerged as key regulators in cancer, influencing gene expression through various mechanisms. This study investigates the role of lncRNAs in mediating MYC function and their impact on breast cancer progression.</div></div><div><h3>Methods</h3><div>We analyzed 1212 breast cancer samples from The Cancer Genome Atlas (TCGA) database to identify lncRNAs related to MYC targets. The expression levels of lncRNAs were correlated with MYC-TARGET scores to develop a prognostic model. Functional studies were performed on LINC00511, a key lncRNA identified in the model, to elucidate its role in breast cancer progression. RNA Immunoprecipitation (RIP), Chromatin Immunoprecipitation (ChIP) and Dual-Luciferase Reporter Gene Assay assays were used to validate interactions between LINC00511, MYC, and the target gene VASP (vasodilator-stimulated phosphoprotein).</div></div><div><h3>Results</h3><div>MYC-TARGET scores were significantly correlated with poor prognosis in breast cancer patients. We identified 38 lncRNAs associated with MYC targets, and LINC00511 was selected for further analysis due to its high expression and correlation with poor prognosis. A prognostic model composed of 5 lncRNAs (including LINC00511) was developed, with a risk score that independently predicted patient outcomes . Functional experiments showed that LINC00511 promoted breast cancer cell proliferation, migration, and invasion. Mechanistically, LINC00511 interacted with MYC to upregulate VASP expression. VASP knockdown significantly reduced breast cancer cell proliferation and migration. Overexpression of MYC rescued the inhibitory effects of LINC00511 knockdown on VASP expression and cell invasion/migration.</div></div><div><h3>Conclusions</h3><div>LINC00511 promotes breast cancer progression by mediating MYC to regulate VASP expression. This study highlights the importance of lncRNAs in cancer transcriptional networks and identifies LINC00511 as a potential therapeutic target for breast cancer.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 3","pages":"Pages 279-296.e1"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis","authors":"Lok-Sze Joyce Au ,&nbsp;Yu-ning Zhang ,&nbsp;Kary Yeung ,&nbsp;Ka-Long Cheung ,&nbsp;Li-Yu Holly Hou ,&nbsp;Mai-Yee Luk ,&nbsp;Ching-Yu Roland Leung ,&nbsp;Wing-Lok Chan","doi":"10.1016/j.clbc.2026.01.007","DOIUrl":"10.1016/j.clbc.2026.01.007","url":null,"abstract":"<div><h3>Background</h3><div>Neoadjuvant chemotherapy combined with dual HER2-targeted therapy improves pathological complete response (pCR) rates in early-stage HER2-positive breast cancer. However, data on its efficacy and tolerability in older adults remain limited.</div></div><div><h3>Objective</h3><div>To evaluate the efficacy, toxicity, and survival outcomes of neoadjuvant dual anti-HER2 therapy in older adults with HER2-positive early breast cancer.</div></div><div><h3>Methods</h3><div>This retrospective cohort included patients with HER2-positive early breast cancer treated with neoadjuvant dual anti-HER2 therapy at Queen Mary Hospital, Hong Kong, between January 2017 and December 2023. Patients were stratified by age (&lt; 65 vs. ≥ 65 years). The primary outcome was pCR. Multivariable logistic regression identified predictors of pCR. Progression-free survival (PFS) was assessed using the Kaplan–Meier method with log-rank testing. Treatment-related toxicities (TRT) were graded according to CTCAE v5.0.</div></div><div><h3>Results</h3><div>A total of 227 patients were included, 43 (18.9%) were aged ≥ 65 years. The pCR rate was 51.2% in older patients and 62.0% in younger patients (<em>P</em> = .194). Higher clinical T-stage was significantly associated with lower pCR (OR = 0.25, 95% CI, 0.06-0.67, <em>P</em> = .02). Older patients experienced more grade ≥ 3 TRT (55.8% vs. 28.3%, <em>P</em> &lt; .001), with neutropenia (32.6% vs. 12.0%) and diarrhoea (16.3% vs. 7.1%) being most common. Unplanned hospitalisations were more frequent (14.0% vs. 4.9%, <em>P</em> = .001). No significant difference in PFS was observed (<em>P</em> = .21). Five-year PFS rates were 87.4% (95% CI, 76.3%-100%) in older patients and 95.2% (95% CI, 92.0-98.6%) in younger patients.</div></div><div><h3>Conclusion</h3><div>Older patients achieved pCR and PFS comparable to younger counterparts but experienced higher toxicity and hospitalisation rates. Age-specific and de-escalation strategies warrant further study.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 3","pages":"Pages 84-93"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Limited English Proficiency With Completion of the Reconstructive Paradigm in Implant-Based Breast Reconstruction","authors":"Ying Yu,&nbsp;Dylan K. Kim,&nbsp;Nadeem E. Jones,&nbsp;Neelam I. Shaikh,&nbsp;Christine H. Rohde","doi":"10.1016/j.clbc.2026.01.009","DOIUrl":"10.1016/j.clbc.2026.01.009","url":null,"abstract":"<div><h3>Background</h3><div>Limited English proficiency (LEP) has been associated with worse postoperative outcomes and lower follow-up in plastic surgery, although its impact in two-stage implant-based breast reconstruction is not well characterized. This study evaluates the effects of LEP on postoperative outcomes in patients who received tissue expander placement for breast reconstruction.</div></div><div><h3>Methods</h3><div>Patients who underwent tissue expander placement for implant-based breast reconstruction were identified within a single urban academic center. LEP was defined as preference for a non-English primary language. Primary outcomes included completion of reconstruction, emergency department (ED) visits, readmissions, and postoperative complications. Multivariable regression models were used to identify independent predictors of ED visits/readmissions, complications, and time to completion of reconstruction (<em>P</em> &lt; .05).</div></div><div><h3>Results</h3><div>The final cohort included 563 patients over a median (IQR) follow-up period of 18.4 (11.0-28.7) months. The rate of overall completion of breast reconstruction was 87.0%. LEP was identified in 171 (30.4%) patients. Rates of breast reconstruction completion (<em>P</em> = .20), ED visits (<em>P</em> = .82), readmissions (<em>P</em> = .38), and postoperative complications (<em>P</em> = .30) were not significantly different depending on LEP status. In a multivariable linear regression model, LEP status was independently associated with a delay in time from TE placement to completion of breast reconstruction (β: 30.9 days, 95% CI, 8.5-53.3, <em>P</em> = .0070). Mean time to completion was 282 days for patients with LEP and 245 days for non-LEP patients.</div></div><div><h3>Conclusion</h3><div>LEP was associated with a delay in time to completion of reconstruction, suggesting delays in surgical care coordination in patients with limited English proficiency.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 3","pages":"Pages 65-73"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146186189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer Scheduled for Mastectomy: A Multidisciplinary Survey; Physicians’ Perspective","authors":"Nina M. Verghis ,&nbsp;Kazim Senol ,&nbsp;Shigeru Imoto ,&nbsp;Claudine Ordoñez ,&nbsp;Kristin Lupinacci ,&nbsp;Jamila Alazhri ,&nbsp;Alexander Mundinger ,&nbsp;Carole Mathelin ,&nbsp;Vahit Ozmen ,&nbsp;Atilla Soran ,&nbsp;Senologic International Society Working Group","doi":"10.1016/j.clbc.2026.01.010","DOIUrl":"10.1016/j.clbc.2026.01.010","url":null,"abstract":"<div><h3>Introduction</h3><div>The number of contralateral risk reduction mastectomies (RRM) continues to rise.</div><div>Despite the existence of many guidelines, there is no general consensus on which patients should be considered for RRM. This survey was distributed among various breast specialists with the goal of evaluating current practices, perspectives, and attitudes towards RRM.</div></div><div><h3>Methods</h3><div>An English-language survey containing ten questions was designed and distributed electronically to members of the Senologic International Society (SIS). The findings of this survey align with existing research and also provide areas for further investigation.</div></div><div><h3>Results</h3><div>This survey demonstrates the different practices and viewpoints on RRM across various specialties and areas around the world. These variations highlight the need for uniform recommendations and further research to enhance patient outcomes and address the challenges of managing RRM patients.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 3","pages":"Pages 44-53"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146186526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Health Issues of Adolescent and Young Adult Breast Cancer Survivors","authors":"Noëlle J.M.C. Vrancken Peeters ,&nbsp;Marianne J. Heins ,&nbsp;Gioele Re ,&nbsp;Marleen Kok ,&nbsp;Iris M.C. van der Ploeg ,&nbsp;Winette T.A. van der Graaf ,&nbsp;Olga Husson","doi":"10.1016/j.clbc.2025.10.009","DOIUrl":"10.1016/j.clbc.2025.10.009","url":null,"abstract":"<div><h3>Background</h3><div>The prognosis for adolescent and young adult (AYA) breast cancer patients has increased significantly. Research concerning long-term health problems is especially relevant given the long life expectancy of these young patients. This study aimed to compare the long-term health issues registered by general practitioners (GPs) of AYA breast cancer survivors to age-matched controls.</div></div><div><h3>Methods</h3><div>Data of all female AYAs diagnosed with invasive breast cancer between 1999 and 2020 were obtained from the Netherlands Cancer Registry (NCR) and linked with longitudinal data on health problems recorded by GPs organized in the Nivel Primary Care Database (Nivel-PCD). A female normative sample was obtained from the Nivel Primary Care Database (Nivel-PCD). Cox proportional hazard models were used to compare the hazard of a GP consult for a specific health condition after diagnosis between AYA breast cancer survivors and controls.</div></div><div><h3>Results</h3><div>A total of 793 AYA breast cancer survivors (mean age 35.3 years, mean follow-up 4.7 years) and 2379 controls were included. AYA breast cancer survivors had significantly increased hazards of consulting the GP for eye (HR = 1.25), musculoskeletal (HR = 1.12), psychological/psychiatric (HR = 1.18), skin (HR = 1.26), and urinary tract conditions (HR = 1.20) and decreased hazards for pregnancy-related conditions (HR = 0.47) and conditions of the female genital system (HR = 0.85) compared to controls.</div></div><div><h3>Conclusion</h3><div>AYA breast cancer survivors face a higher risk of various long-term health challenges compared to age-matched controls, including physical and psychological conditions. This emphasizes the need for the development of multidisciplinary follow-up programs tailored to the specific and ongoing health needs of this young population.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 3","pages":"Pages 200-207.e4"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145502472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare-Related Determinants of Breast Cancer Prognosis in São Paulo, Brazil: A Population-Based Cohort","authors":"Gustavo Nader Marta ,&nbsp;Allan Andresson Lima Pereira ,&nbsp;Carlos Henrique Dos Anjos ,&nbsp;Rudinei Diogo Marques Linck ,&nbsp;Daniel de Araujo Brito Buttros ,&nbsp;Lincon Jo Mori ,&nbsp;Samir Abdallah Hanna ,&nbsp;André Guimarães Gouveia ,&nbsp;Fabio Ynoe de Moraes","doi":"10.1016/j.clbc.2025.09.015","DOIUrl":"10.1016/j.clbc.2025.09.015","url":null,"abstract":"<div><h3>Purpose/Objective</h3><div>To compare demographic characteristics, stage at diagnosis, treatment patterns, and survival outcomes of breast cancer patients treated in Brazil's public and private healthcare systems.</div></div><div><h3>Materials and methods</h3><div>This retrospective cohort study analyzed data from the Fundação Oncocentro de São Paulo, including women diagnosed with invasive breast cancer between January 2000 and June 2020. Overall survival (OS) was estimated using Kaplan-Meier methods and log-rank tests. Prognostic factors were evaluated using Cox proportional hazards models.</div></div><div><h3>Results</h3><div>A total of 65,543 patients were included. Age distribution was similar between the public and private sectors. However, early-stage diagnoses (stages I and II) were significantly more frequent in the private sector (77.8%), whereas the public system had a higher proportion of patients diagnosed at advanced stages (67.8% in stages II and III) and with metastatic disease (11.1% vs. 5.3%). The proportion of patients receiving surgery and at least 2 adjuvant therapies (trimodal therapy) was comparable between sectors (46.6% private vs. 46.2% public). Survival analysis demonstrated consistently higher 5- and 10-year OS across all stages in the private sector. Ten-year OS by stage was: I–81.6% (private) versus 77.5% (public), <em>P</em> &lt; .001; II–74.0% vs. 63.3%, <em>P</em> &lt; .001; III–55.6% versus 39.6%, <em>P</em> &lt; .001; IV–7.6% versus 6.4%, <em>P</em> = .306. Multivariate analysis identified treatment in the private sector, younger age at diagnosis, higher education level, receipt of trimodal therapy, and earlier stage as independent predictors of improved OS.</div></div><div><h3>Conclusion</h3><div>Breast cancer patients treated in the public healthcare system in Brazil more often present with advanced disease, which is associated with inferior survival outcomes.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 2","pages":"Pages 281-286"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Multi-Biomarker Nomogram Combining CD155/CD226/TIGIT/CD96 Immune Checkpoint Axis for Postoperative Survival Prediction in Breast Cancer","authors":"Xin Ou ,&nbsp;Feng Shi ,&nbsp;Yanjie Zhao ,&nbsp;Quan Zhou ,&nbsp;Keyu Yuan ,&nbsp;Shuzhen Lyu ,&nbsp;Jiangping Wu ,&nbsp;Yanping Li ,&nbsp;Qingkun Song","doi":"10.1016/j.clbc.2025.09.004","DOIUrl":"10.1016/j.clbc.2025.09.004","url":null,"abstract":"<div><h3>Background</h3><div>The CD155-CD226/CD96/TIGIT axis, a novel immune checkpoint, showed aberrant expression in breast cancer (BC) and associated with prognosis. This study developed and validated a prognostic model combining these molecules with clinical factors to create a visual tool for individualized BC prognosis.</div></div><div><h3>Methods</h3><div>Immunohistochemistry assessed CD155, CD226, CD96, and TIGIT expression in the tumor microenvironment (TME). A prognostic index (PI) was constructed based on the expression profiles of these 4 molecules, and survival prediction models incorporating the PI and clinicopathological factors were developed using multivariate Cox regression analysis. Model performance and clinical utility were assessed via the C-index, receiver operating characteristic (ROC) curves, Brier score, calibration plots, and decision curve analysis (DCA). Internal validation of model was conducted using 1000-bootstrap resampling.</div></div><div><h3>Results</h3><div>The PI stratified patients into high/low-risk groups with distinct survival outcomes. Nomograms incorporating the PI and clinical factors demonstrated robust performance. The C-index was 0.772 (bootstrapped corrected: 0.785) for disease-free survival (DFS) and 0.822 (bootstrapped corrected: 0.824) for overall survival (OS). Time-dependent areas under the ROC curve were ≥ 0.80 for 3-, 5-, and 8-year DFS prediction and ≥ 0.85 for OS prediction. Calibration plots showed excellent agreement between predicted and observed survival outcomes, and DCA confirmed the clinical net benefit of the model. Sensitivity analyses also further validated model robustness.</div></div><div><h3>Conclusions</h3><div>This study established a novel prognostic tool for BC by combining TME markers with clinicopathological factors. The developed nomograms enabled accurate individualized risk stratification and demonstrated clinical utility, offering a framework for precision oncology to survival prediction.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 2","pages":"Pages 238-247.e3"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145273941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cryoablation for Treatment of Early-Stage Breast Cancer: Efficacy and Quality of Life Assessment","authors":"Jacopo Nori Cucchiari ,&nbsp;Federica Di Naro ,&nbsp;Giuliano Migliaro ,&nbsp;Sofia Elisabetta Baldi Giorgi ,&nbsp;Francesca Pugliese ,&nbsp;Tommaso Amadori ,&nbsp;Giulia Bicchierai ,&nbsp;Diego De Benedetto ,&nbsp;Chiara Bellini ,&nbsp;Sofia Vidali ,&nbsp;Ermanno Vanzi ,&nbsp;Cecilia Boeri ,&nbsp;Verdiana Lamagna ,&nbsp;Vittorio Miele ,&nbsp;Tommaso Susini","doi":"10.1016/j.clbc.2025.12.004","DOIUrl":"10.1016/j.clbc.2025.12.004","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer (BC) is the most common cancer among women. There has been growing interest in less invasive techniques for the treatment of breast lesions, with cryoablation emerging as promising option. We aimed to assess the safety and efficacy of cryoablation for the treatment of breast cancer tumor subtypes 12 months post-treatment.</div></div><div><h3>Methods</h3><div>This single-center prospective study included patients with biopsy-proven BC who underwent ultrasound-guided-cryoablation treatment during 2021-2023. Locoregional staging was performed using ultrasound and contrast-enhanced mammography (CEM). Follow-up included ultrasound at 1-, 3-, 6- and 12-months with additional CEM and biopsy at 12-months. Rate of complete ablation, tumor size and quality of life (QoL) were assessed. Primary endpoint was absence of residual tumor for BC at 12-month post cryoablation.</div></div><div><h3>Results</h3><div>Thirthy-six female patients (mean age, 84.5±6.7 years) with 39 biopsy-proven tumors (mean size 15.3±7.5 mm) underwent cryoablation. No device-related unexpected adverse events were reported. The 39 BCs were early-stage luminal A or B, invasive ductal carcinoma (IDC) or IDC + ductal carcinoma in situ. Complete ablation rates for BC ≤ 15 mm and BC &gt;15 mm were 100% and 84.6%, respectively; Cryoablation positively impacted patient QoL as assessed by validated questionnaires.</div></div><div><h3>Conclusions</h3><div>With improved QoL, cryoablation emerges as a promising, safe, and effective treatment option for low-risk breast cancer.</div></div><div><h3>Disclaimer/Publisher’s Note</h3><div>The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 2","pages":"Pages 70-79"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146035567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Benefit of Adjuvant Capecitabine According To Residual Cancer Burden in Patients With Triple-Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy","authors":"Shinyoung Lee ,&nbsp;Hyehyun Jeong ,&nbsp;Eunju Shin ,&nbsp;Sae Byul Lee ,&nbsp;Jae Ho Jeong ,&nbsp;Hee Jin Lee ,&nbsp;Gyungyub Gong ,&nbsp;Min-Ju Kim ,&nbsp;Hee Jeong Kim ,&nbsp;Jong Won Lee ,&nbsp;Byung-Ho Son ,&nbsp;Jaewon Hyung ,&nbsp;Jin-Hee Ahn ,&nbsp;Kyung Hae Jung ,&nbsp;Sung-Bae Kim","doi":"10.1016/j.clbc.2025.09.006","DOIUrl":"10.1016/j.clbc.2025.09.006","url":null,"abstract":"<div><h3>Background</h3><div>In early triple-negative breast cancer (TNBC), surgery following neoadjuvant chemotherapy (NAC) is standard. Adjuvant capecitabine has shown survival benefits in patients with residual disease; however, data remain limited regarding the subgroups that benefit most, particularly when stratified by residual cancer burden (RCB), a key prognostic indicator post-NAC.</div></div><div><h3>Methods</h3><div>Patients with early TNBC and residual disease following NAC (Feb 2008-Dec 2021) were retrospectively included. After propensity score matching to balance baseline characteristics, recurrence-free survival (RFS) was compared between patients who received adjuvant capecitabine and those who did not.</div></div><div><h3>Results</h3><div>Of 828 eligible patients, 631 were included in the final propensity score matched analysis (222 capecitabine; 409 observation). Median ages were 48 years (range, 40-56) and 50 years (range, 41-56) in the observation and capecitabine groups. RCB distribution was comparable between groups: RCB-I (10% vs. 11%), RCB-II (68% in both), and RCB-III (22% vs. 21%). RCB was prognostic across the cohort, with 3-year RFS rates of 92.2%, 73.6%, and 43.3% for RCB-I, -II, and -III, respectively. Adjuvant capecitabine improved RFS in RCB-III (HR, 0.6; 95% CI, 0.3-0.9; <em>P</em> = .02), but not in RCB-I (HR, 1.1; 95% CI, 0.2-6.5; <em>P</em> = .93) or RCB-II (HR, 0.9; 95% CI, 0.7-1.4; <em>P</em> = .84). In RCB-III, distant metastasis occurred less frequently in the capecitabine group compared with the observation group (34.0% vs. 62.9%).</div></div><div><h3>Conclusion</h3><div>Adjuvant capecitabine was most beneficial in patients with RCB-III disease, primarily through a reduction in distant metastasis. These findings support its selective use in high-risk TNBC populations.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 2","pages":"Pages 248-258.e2"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Efficacy and Safety of NEOadjuvant CHEmoimmunotherapy in Early ER-Low/HER2-Negative Breast Cancer (NEOCHEER): A Systematic Review and Meta-Analysis","authors":"Jessé Lopes da Silva ,&nbsp;Luís Felipe Leite da Silva ,&nbsp;Wallace Klein Schwengber ,&nbsp;Lucas Zanetti de Albuquerque ,&nbsp;Natália Cristina Cardoso Nunes ,&nbsp;Andréia Cristina de Melo","doi":"10.1016/j.clbc.2025.09.017","DOIUrl":"10.1016/j.clbc.2025.09.017","url":null,"abstract":"<div><div>To evaluate the efficacy and safety of neoadjuvant chemoimmunotherapy in patients with early-stage estrogen receptor (ER)-low/HER2-negative breast cancer (BC), a population often overlooked in clinical trials. A systematic review and meta-analysis were conducted following preferred reporting items for systematic reviews and meta-analyses (PRISMA) standards and registered with PROSPERO. Comprehensive searches were performed across PubMed, Cochrane CENTRAL, Embase, and major oncology conferences for studies with data on neoadjuvant chemoimmunotherapy in ER-low BC. The primary endpoint was the pathologic complete response (pCR) rate, with a secondary descriptive analysis of safety data. Seven studies encompassing 260 patients with ER-low BC were included (3 cohorts and 4 clinical trials). All studies utilized humanized anti-PD-1 antibodies, with 4 administering pembrolizumab, 1 using nivolumab, and 1 employing camrelizumab. The overall pooled pCR rate for ER-low BC was 64.88% (95% confidence interval [CI], 56.72%-73.04%; I² = 37.5%). No significant differences in pCR rates were identified between clinical trials and cohort studies (<em>P</em> = .724). Adverse event data were reported in 2 studies, revealing that 34.4% of patients experienced hospitalizations, with notable rates of grade ≥ 3 adverse events (AEs) and immune-related AEs (irAEs). Neoadjuvant chemoimmunotherapy shows high rates of pCR for ER-low BC, resembling triple-negative BC, with safety data indicating fewer severe complications than observed in pivotal trials.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 2","pages":"Pages 296-303"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145421343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}